Government health authorities consider task force for psychedelic, entactogenic therapy testing within 2 years

Representatives of HHS are considering creating a task force to guide the use of FDA breakthrough psychedelic mental health therapies within the next two years, a letter obtained last week by political news organization the Intercept said.

The letter was sent on behalf of HHS to Rep. Madeleine Dean, D-Pa., who first proposed creating task force.

Dated May 13, the letter said, "[The substance abuse and mental health services administration], in collaboration with the assistant secretary for health, is exploring the prospect of establishing a Federal Task Force to monitor and address the numerous complex issues associated with emerging substances."

The letter was shared with the Intercept July 26. It expressed support for an amended Right to Try legislation, co-sponsored by U.S. Sens.Cory Booker, D-N.J., and Rand Paul, R-Ky. The bipartisan bill that pushes for patients with life-threatening conditions who have tried all approved treatment options to access certain treatments not yet approved by the FDA. 

The letter anticipated that the FDA will approve methylenedioxymethamphetamine (MDMA) and psilocybin treatments for post-traumatic stress disorder and depression within the next two years. 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Whitepapers

Featured Webinars

Top 40 articles from the past 6 months